to Evaluate the Efficacy and Safety of CM336 (BCMA/CD3 Bispecific Antibody) in Adults with Moderate to Severe Autoimmune Bullous Disease
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
30
subcutaneous CM336 administration
Dermatology Hospital Affiliated to Shandong First Medical University
Jinan, China
RECRUITINGTo evaluate the efficacy after CM336 treatment
Proportion of subjects in remission
Time frame: Up to 52 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.